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Matricryptins*Wolfram-Hubertus Zimmermann, MDSEE PAGE 1364P roteolytic cleavage of extracellular matrix(ECM) proteins is a highly (dys)regulated bio-logical process in the healthy and diseased
heart (1). ECM cleavage products, such as the N-termi-
nal fragment of type I collagen (procollagen I N-termi-
nal peptide), the carboxy-terminal telopeptide of
type I collagen, and the N-terminal fragment of type
III collagen, are frequently used as biomarkers for
collagen type I synthesis, collagen type I degradation,
and collagen type III synthesis, respectively. A prom-
inent example is detection of elevated carboxy-
terminal telopeptide of type I collagen blood levels
in patients with particularly poor outcomes in EPHE-
SUS (Eplerenone Post-Acute Myocardial Infarction
Heart Failure Efﬁcacy and Survival Study) (2). Many
additional ECM and apparently ﬁbrosis-associated
circulating biomarkers have been introduced, but
their predictive value in clinical trials remains,
for the most part, elusive (3). More recently, it has
become apparent that ECM cleavage products may
be more than just innocent bystanders in myocar-
dial remodeling processes, because some appear to
encompass disease-modifying biological activity.
For those, the term matricryptins has been intro-
duced (4). Matricryptins are cleaved from various
ECM proteins, including collagens, elastin, and
hyaluronan.*Editorials published in the Journal of the American College of Cardiology
reﬂect the views of the authors and do not necessarily represent the
views of JACC or the American College of Cardiology.
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of this paper to disclose.By far the most abundant ECM proteins in the
heart, collagen types I and III exhibit intricate struc-
tural and signaling functions (5). Post-myocardial
infarction (MI) collagen deposition helps to maintain
the mechanical strength of the affected ventricular
wall. It is, however, important to realize that
the process of post-infarct wound healing must be
ﬁne-tuned to avoid excessive ﬁbrosis or dilation
because of insufﬁcient mechanical stability. Ventric-
ular ﬁbrosis is, for the most part, irreversible and will
progressively result in weakening of myocardial
performance and an increased incidence of elec-
trophysiological re-entry. Finally, a balance of ECM
production and turnover is essential in possibly all
disease processes affecting the heart.
Matrix metalloproteinase (MMP)-2, also known as
gelatinase A, and MMP-9 (or gelatinase B) are key
collagen-degrading enzymes in the heart with broad
and partially overlapping substrate speciﬁcity (6).
MMP-9 is strongly up-regulated in the acutely
infarcted heart (7) and secreted predominantly by
activated macrophages (6). Also, in mouse models,
MMP-9 is similarly up-regulated acutely after MI and
correlates directly with left ventricular (LV)
dysfunction; interestingly, MMP-9–deﬁcient mice
exhibited better LV function post-MI (8).In this issue of the Journal, Lindsey et al. (9)
identiﬁed a previously unrecognized MMP-2 and -9
cleavage site within the collagen type I protein.
Cleavage at this site resulted in release of an 18-kD
peptide fragment (C-1158/59). In a mouse model of
MI, C-1158/59 was elevated markedly in infarcted, but
not remote myocardium. The highest C-1158/59
abundance was observed after the acutely increased
MMP-9 activity returned to baseline levels 7 days
FIGURE 1 LV Preservation With C-1158/59
The peptide fragment C-1158/59 is released from a matrix metalloproteinase (MMP)-2
and -9 cleavage site; while contributing to its appearance, MMP9 also suppresses its ac-
tivity via peptide degradation. Previous studies have demonstrated potential wound
healing properties of C-1158/1159; in the study from Lindsey et al. (9), a C-1158/1159
peptide mimetic produced less left ventricular (LV) dilation and ﬁbrosis, possibly via a shift
in collagen type I and III ratio.
Zimmermann J A C C V O L . 6 6 , N O . 1 2 , 2 0 1 5
Matricryptins: Brave New World of Biologics S E P T E M B E R 2 2 , 2 0 1 5 : 1 3 7 5 – 7
1376post-MI. This ﬁnding was in agreement with the
observed degradation of C-1158/59 under extended
exposure to MMP-9, suggesting that MMP-9, poten-
tially together with other MMPs, on the one hand
contributes to the appearance of C-1158/59 (by
collagen type I cleavage), while on the other hand
suppressing its biological activity (by peptide degra-
dation) (Figure 1).
Cell culture experiments demonstrated enhanced
mouse cardiac ﬁbroblast migration and capillary for-
mation in human umbilical vein endothelial cells in
the presence of C-1158/59. Thus, the authors
conceptualized that these biological activities may
aid wound healing if stabilized shortly after MI. To
test this hypothesis, a 15 amino acid peptide mimetic
of the C-1158/59 cleavage product was synthesized
and applied via osmotic mini-pumps for 7 days,
starting 3 h post-MI induced by permanent occlusion
of the left anterior descending coronary artery. In this
proof-of-concept study, less LV dilation and collagen
type I deposition (i.e., less ﬁbrosis) with concomi-
tantly enhanced type III collagen was observed in
the C-1158/59 peptide-treated mouse cohort. The
shift in collagen type I and III ratio may constitute
the mechanistic underpinning for the observedpreservation of LV geometry in the C-1158/59 group
(Figure 1). Interestingly, enhanced capillarization
without evidence for cardiomyocyte atrophy was
observed in not only the infarcted but also remote
myocardium. This could have further contributed to
the observed advantageous wound healing processes.
Finally, evidence for a pathophysiological role of
endogenous C-1158/59 was provided by analyzing
blood samples from patients taken 24 to 48 h after MI.
Enhanced venous blood levels of C-1158/59 correlated
negatively with LV ﬁlling, suggesting that therapeutic
elevation of C-1158/59 could have a beneﬁcial effect
on disease progression.
Identifying a small peptide fragment with biolog-
ical activity on the post-infarct tissue scarring pro-
cesses is highly attractive because it offers the
opportunity for biotechnological mass production
and protein engineering for enhanced activity as well
as speciﬁcity. It may also facilitate the discovery of
new molecular entities with more favorable pharma-
cokinetic and pharmacodynamic properties. Lindsey
et al. (9) provide the ﬁrst hints for the therapeutic
efﬁcacy of C-1158/59. However, further pre-clinical
data are needed to scrutinize its mode of action,
timing, and dosing. Also, it will be necessary to
determine long-term effects, including unwanted and
off-target effects, before considering clinical trials
with hard endpoints, such as time to the development
of symptomatic heart failure (HF) and death from HF
or associated arrhythmias.
Targeting ﬁbroblast and endothelial function after
MI for therapeutic modulation of wound healing is
conceptually interesting, as it offers a new therapeutic
direction in times where protection from neuro-
humoral overstimulation (with beta-adrenoceptor
blockers and inhibitors of the renin-angiotensin-
aldosterone system) appears to have reached its
maximal, but still insufﬁcient, clinical effect. For
synthetic C-1158/59, we now see preliminary proof of
concept for biological and, importantly, disease-
modifying activity—albeit with no long-term follow-
up and limited functional data. The association of
C-1158/59 blood levels with disease progression in the
post-infarction setting in humans is an important
observation, as it supports the validity of the mouse
model in early pre-clinical studies in this line of drug
development. To enhance our fundamental knowl-
edge and inform clinical translation, additional pre-
clinical studies in arguably more relevant disease
models should be considered (e.g., a large animal
modelwith ischemia-reperfusion injury). Importantly,
off-target effects must be anticipated if a fundamental
process such as ECM homeostasis is therapeutically
targeted. Consequently, delivery methods speciﬁc to
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1377the heart and more speciﬁcally to the area of infarc-
tion may have to be developed. Myocardial gene
delivery via viral vectors with cardiac tropism might
solve this challenge (10).
Finally, a word of caution: we have observed
many exceptionally effective innovative therapeutics
in mouse models in the past decades. Few, if any,
have found a clinical application. This may, in part,
be due to the limited translational value of rodent
models, suboptimal patient selection in early clinical
trials, or lack of efﬁcacy on top of state-of-the-art
therapy. Despite this caveat and in light of the
limited therapeutic options in the globally growing
population of patients with HF, the data on theC-1158/59 matricryptin and the general concept of
targeting the early remodeling process after MI are
highly attractive. Considering the myocardial stroma
cells and the myocardial stroma itself as primary
targets for HF therapy promises a paradigm shift
from today’s cardiomyocyte-centric approach to HF
therapeutics.
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